在中国中部的低教育人口中实施血p-tau217和用于阿尔茨海默病查的认知测试
Shuai Chen1, Xiaodi Hao1, Kai Ma1
1Department of Neurology, Zhengzhou University People's Hospital (Henan Provincial People's Hospital), Zhengzhou, China.
概括
一种新的查策略结合了认知测试和化的tau217 (p-tau217) 来检测老年人的认知障碍. 这种方法有助于在社区环境中早期检测和生物标志物实施.
科学领域:
- 老年学是一门学科.
- 神经学 神经学
- 生物标志物发现发现
背景情况:
- 在老年人群中进行认知障碍查对于早期干预至关重要.
- 血生物标志物为传统诊断方法提供了一种不那么侵入性的替代方案.
研究的目的:
- 通过认知评估和血p-tau217.217.使用实用查策略进行评估.
- 评估将血生物标志物整合到社区健康查中的可行性.
主要方法:
- 一组老年人接受了记忆和执行查 (MES) 测试和血p-tau217测量.
- 认知障碍是使用残留规范来定义的,p-tau217值是为正预测值 (PPV) 进行优化.
主要成果:
- 12.4%的参与者表现出MES定义的认知障碍.
- 在没有认知障碍的个体中,p-tau217阳性因年龄而异,在≥70岁的个体中达到25.9%.
- 26.6%的认知障碍参与者是p-tau217阳性.
结论:
- 综合查策略对于将血生物标志物整合到社区环境中是切实可行的.
- 需要进一步的纵向研究来完善生物标志物值.
- 这种方法支持早期检测,临床试验招聘和资源分配,特别是在服务不足的地区.
相关概念视频
01:26Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
01:22Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K